Capex

Primær information

  • Handelsnavn:
  • Capex Suspensionskoncentrat
  • Lægemiddelform:
  • Suspensionskoncentrat
  • Sammensætning:
  • 10 g/l Adoxophyes orana granulose virus
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Capex Suspensionskoncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Ikke længere markedsført
  • Autorisationsnummer:
  • 748-1
  • Sidste ændring:
  • 08-02-2018

Indlægsseddel

13-2-2018

Acyclovir 400mg Tablets by Apace Packaging: Recall - Product Mix-up

Acyclovir 400mg Tablets by Apace Packaging: Recall - Product Mix-up

Missing a dose of Acyclovir Tablets could cause a reactivation of a virus being treated.

FDA - U.S. Food and Drug Administration

13-2-2018

Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)

Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)

El 20 de enero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que ha identificado como factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) la detección en pruebas de anticuerpos contra el virus JC. PML es una infección poco común pero grave del cerebro relacionada con el uso de Tysabri (natalizumab) para el tratamiento de esclerosis múltiple o enfermedad de Crohn.

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)

FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)

[01-20-2012] The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML).

FDA - U.S. Food and Drug Administration

11-12-2017

FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs

FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs

The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended at this time because of the possibility of reducing the effectiveness of the medicines, permitting the amount of HCV or HIV virus in the blood (viral load) to increase.

FDA - U.S. Food and Drug Administration

21-11-2017

FDA approves first two-drug regimen for certain patients with HIV

FDA approves first two-drug regimen for certain patients with HIV

FDA approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.

FDA - U.S. Food and Drug Administration

5-10-2017

FDA approves first test for screening Zika virus in blood donations

FDA approves first test for screening Zika virus in blood donations

The U.S. Food and Drug Administration today approved the cobas Zika test, a qualitative nucleic acid test for the detection of Zika virus RNA in individual plasma specimens obtained from volunteer donors of whole blood and blood components, and from living organ donors.

FDA - U.S. Food and Drug Administration

19-4-2018

Epstein-Barr Virus Protein and Autoimmune Diseases

Epstein-Barr Virus Protein and Autoimmune Diseases

Epstein-Barr Virus Protein Can 'Switch On' Risk Genes for Autoimmune Diseases

US - eMedicineHealth

18-4-2018

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)

EU/3/18/2012 (IDEA Innovative Drug European Associates Limited)

EU/3/18/2012 (Active substance: Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII) - Orphan designation - Commission Decision (2018)2408 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/17

Europe -DG Health and Food Safety

18-4-2018

Can 'Mono' Virus Up Odds for 7 Other Diseases?

Can 'Mono' Virus Up Odds for 7 Other Diseases?

Title: Can 'Mono' Virus Up Odds for 7 Other Diseases?Category: Health NewsCreated: 4/16/2018 12:00:00 AMLast Editorial Review: 4/17/2018 12:00:00 AM

US - MedicineNet

13-4-2018

Zulvac 8 Ovis (Zoetis Belgium S.A.)

Zulvac 8 Ovis (Zoetis Belgium S.A.)

Zulvac 8 Ovis (Active substance: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* = 1) - Centralised - Yearly update - Commission Decision (2018)2244 of Fri, 13 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Zulvac 1 Bovis (Zoetis Belgium S.A.)

Zulvac 1 Bovis (Zoetis Belgium S.A.)

Zulvac 1 Bovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP = 1) - Centralised - Yearly update - Commission Decision (2018)2127 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Zulvac 1 Ovis (Zoetis Belgium S.A.)

Zulvac 1 Ovis (Zoetis Belgium S.A.)

Zulvac 1 Ovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP = 1) - Centralised - Yearly update - Commission Decision (2018)2128 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

6-4-2018

Zulvac 8 Bovis (Zoetis Belgium S.A.)

Zulvac 8 Bovis (Zoetis Belgium S.A.)

Zulvac 8 Bovis (Active substance: Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02 RP* = 1) - Centralised - Yearly update - Commission Decision (2018)2129 of Fri, 06 Apr 2018

Europe -DG Health and Food Safety

29-3-2018

Zulvac SBV (Zoetis Belgium S.A.)

Zulvac SBV (Zoetis Belgium S.A.)

Zulvac SBV (Active substance: Inactivated Schmallenberg virus, strain BH80/11-4) - Centralised - Yearly update - Commission Decision (2018)2057 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Versican Plus DHPPi/L4 (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4 (Zoetis Belgium S.A.)

Versican Plus DHPPi/L4 (Active substance: Vaccine against canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza-2 virus and leptospirosis) - Centralised - Yearly update - Commission Decision (2018)2059 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Versican Plus DHPPi (Zoetis Belgium S.A.)

Versican Plus DHPPi (Zoetis Belgium S.A.)

Versican Plus DHPPi (Active substance: Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza type 2 virus) - Centralised - Yearly update - Commission Decision (2018)2058 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Zulvac 1+8 Ovis (Zoetis Belgium S.A.)

Zulvac 1+8 Ovis (Zoetis Belgium S.A.)

Zulvac 1+8 Ovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 / Inactivated Bluetongue Virus, serotype 8, strain BTV-8/BEL2006/02) - Centralised - Yearly update - Commission Decision (2018)2061 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

29-3-2018

Zulvac 1+8 Bovis (Zoetis Belgium S.A.)

Zulvac 1+8 Bovis (Zoetis Belgium S.A.)

Zulvac 1+8 Bovis (Active substance: Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 / Inactivated Bluetongue Virus, serotype 8, strain BTV-8/BEL2006/02) - Centralised - Yearly update - Commission Decision (2018)2062 of Thu, 29 Mar 2018

Europe -DG Health and Food Safety

26-3-2018

Suvaxyn PCV (Zoetis Belgium S.A.)

Suvaxyn PCV (Zoetis Belgium S.A.)

Suvaxyn PCV (Active substance: Porcine circovirus recombinant virus (cpcv) 1-2, inactivated) - Centralised - Yearly update - Commission Decision (2018)1927 of Mon, 26 Mar 2018

Europe -DG Health and Food Safety

26-3-2018

Suvaxyn CSF Marker (Zoetis Belgium S.A.)

Suvaxyn CSF Marker (Zoetis Belgium S.A.)

Suvaxyn CSF Marker (Active substance: Live Recombinant E2 gene deleted Bovine Viral Diarrhoea Virus containing Classical Swine Fever E2 (CP7_E2alf)) - Centralised - Yearly update - Commission Decision (2018)1928 of Mon, 26 Mar 2018

Europe -DG Health and Food Safety

22-3-2018

Oncept IL-2 (Merial)

Oncept IL-2 (Merial)

Oncept IL-2 (Active substance: Feline interleukin-2 recombinant canarypox virus (vCP1338)) - Centralised - Renewal - Commission Decision (2018)1848 of Thu, 22 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2562/R/6

Europe -DG Health and Food Safety

10-3-2018

Mosquitoes Spreading Zika Virus in Parts of U.S.: CDC

Mosquitoes Spreading Zika Virus in Parts of U.S.: CDC

Title: Mosquitoes Spreading Zika Virus in Parts of U.S.: CDCCategory: Health NewsCreated: 3/8/2018 12:00:00 AMLast Editorial Review: 3/9/2018 12:00:00 AM

US - MedicineNet

22-2-2018

Vectormune ND (CEVA-Phylaxia Co. Ltd.)

Vectormune ND (CEVA-Phylaxia Co. Ltd.)

Vectormune ND (Active substance: Cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain) - Centralised - 2-Monthly update - Commission Decision (2018)1182 of Thu, 22 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3829/II/7

Europe -DG Health and Food Safety

13-2-2018

Shining a Deadly New Light on Airborne Flu Virus

Shining a Deadly New Light on Airborne Flu Virus

Title: Shining a Deadly New Light on Airborne Flu VirusCategory: Health NewsCreated: 2/12/2018 12:00:00 AMLast Editorial Review: 2/12/2018 12:00:00 AM

US - MedicineNet

9-2-2018

Variant Influenza Virus Swine Flu Symptoms

Variant Influenza Virus Swine Flu Symptoms

Variant Influenza Virus (Swine Flu) Symptoms

US - eMedicineHealth

7-2-2018

Got a Pet Rat? Watch Out for This Scary New Virus

Got a Pet Rat? Watch Out for This Scary New Virus

Title: Got a Pet Rat? Watch Out for This Scary New VirusCategory: Health NewsCreated: 2/5/2018 12:00:00 AMLast Editorial Review: 2/6/2018 12:00:00 AM

US - MedicineNet

2-2-2018

West Nile Virus May Pose Zika-Like Threat to Fetus

West Nile Virus May Pose Zika-Like Threat to Fetus

Title: West Nile Virus May Pose Zika-Like Threat to FetusCategory: Health NewsCreated: 1/31/2018 12:00:00 AMLast Editorial Review: 2/1/2018 12:00:00 AM

US - MedicineNet

26-1-2018

Cervarix (GlaxoSmithKline Biologicals S.A.)

Cervarix (GlaxoSmithKline Biologicals S.A.)

Cervarix (Active substance: Human Papilloma Virus-16 and Human Papilloma Virus 18 L1 proteins) - Centralised - Yearly update - Commission Decision (2018)547 of Fri, 26 Jan 2018

Europe -DG Health and Food Safety

19-1-2018

MORBILLINUM (Measles Virus) Liquid [Washington Homeopathic Products]

MORBILLINUM (Measles Virus) Liquid [Washington Homeopathic Products]

Updated Date: Jan 19, 2018 EST

US - DailyMed

16-1-2018

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Yearly update - Commission Decision (2018)230 of Tue, 16 Jan 2018

Europe -DG Health and Food Safety

11-1-2018

Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

Title: Human Immunodeficiency Virus (HIV)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/11/2018 12:00:00 AM

US - MedicineNet

9-1-2018

Respiratory Virus Lurks as Wintertime Worry

Respiratory Virus Lurks as Wintertime Worry

Title: Respiratory Virus Lurks as Wintertime WorryCategory: Health NewsCreated: 1/7/2018 12:00:00 AMLast Editorial Review: 1/8/2018 12:00:00 AM

US - MedicineNet

29-12-2017

Human Cold Virus Killed Chimpanzees

Human Cold Virus Killed Chimpanzees

Title: Human Cold Virus Killed ChimpanzeesCategory: Health NewsCreated: 12/27/2017 12:00:00 AMLast Editorial Review: 12/28/2017 12:00:00 AM

US - MedicineNet

20-12-2017

HBVAXPRO (MSD VACCINS)

HBVAXPRO (MSD VACCINS)

HBVAXPRO (Active substance: Recombinant Hepatitis B virus small surface antigen (HbsAg)) - Centralised - Yearly update - Commission Decision (2017)8997 of Wed, 20 Dec 2017

Europe -DG Health and Food Safety

28-11-2017

Zika Nerve Damage May Stem From Body's Response to the Virus

Zika Nerve Damage May Stem From Body's Response to the Virus

Title: Zika Nerve Damage May Stem From Body's Response to the VirusCategory: Health NewsCreated: 11/27/2017 12:00:00 AMLast Editorial Review: 11/28/2017 12:00:00 AM

US - MedicineNet

23-11-2017

Bovilis Blue-8 (Intervet International B.V.)

Bovilis Blue-8 (Intervet International B.V.)

Bovilis Blue-8 (Active substance: Bluetongue virus vaccine (inactivated) serotype 8) - Centralised - Authorisation - Commission Decision (2017)7894 of Thu, 23 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/V/C/4776

Europe -DG Health and Food Safety

21-11-2017

Ebola Virus Disease (Ebola Hemorrhagic Fever)

Ebola Virus Disease (Ebola Hemorrhagic Fever)

Ebola (Ebola Hemorrhagic Fever or Ebola Virus Disease)

US - eMedicineHealth

17-11-2017

Imvanex (Bavarian Nordic A/S)

Imvanex (Bavarian Nordic A/S)

Imvanex (Active substance: modified vaccinia ankara virus) - Centralised - Yearly update - Commission Decision (2017)7739 of Fri, 17 Nov 2017

Europe -DG Health and Food Safety

30-10-2017

News and press releases:  How to develop vaccines and medicines that prevent and treat respiratory syncytial virus (RSV) infection

News and press releases: How to develop vaccines and medicines that prevent and treat respiratory syncytial virus (RSV) infection

New guideline to facilitate development of vaccines and treatments out for consultation until April 2018

Europe - EMA - European Medicines Agency

30-10-2017

Scientific guideline:  Draft guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease, draft: consultation open

Scientific guideline: Draft guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease, draft: consultation open

The guideline covers the clinical development of vaccines and monoclonal antibodies for the prevention of RSV disease and direct acting antiviral agents for the treatment of RSV disease. The focus is on the assessment of safety and efficacy in populations most likely to develop RSV lower respiratory tract infection and severe RSV disease, including (newborn) infants and toddlers, older children predisposed to develop severe RSV disease and the elderly. The guideline also addresses vaccination of pregnant...

Europe - EMA - European Medicines Agency

11-10-2017

Ambirix (GlaxoSmithKline Biologicals S.A.)

Ambirix (GlaxoSmithKline Biologicals S.A.)

Ambirix (Active substance: Inactivated hepatitis A virus, Hepatitis B surface antigen (rDNA)) - Centralised - Yearly update - Commission Decision (2017)6900 of Wed, 11 Oct 2017

Europe -DG Health and Food Safety

6-10-2017

FDA OKs First Test to Screen Zika Virus in Donated Blood

FDA OKs First Test to Screen Zika Virus in Donated Blood

A test for screening donated blood for the Zika virus that was pressed into service on an experimental basis during last year's red-alert outbreak was approved today by the US Food and Drug Administration (FDA).

US - RxList